Skip to main content

Table 1 Characteristics of the 10 studies included in the meta-analysis

From: Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis

Studies

Patients (N)

Treatment

Diabetes duration (months)

Adiponectin (μg/mL)

HbA1c (%)

Treatment duration (months)

Patient characteristics

BMI (kg/m2)

Age (years)

Male (N)

Weight (kg)

Derosa, 2012 [22]

91

sitagliptin + metformin

5.8

5.0

8.1

12

28.1

55.9

42

78.4

 

87

placebo + metformin

5.4

5.2

8.0

 

28.9

54.8

44

78.6

Derosa, 2010 [23]

75

sitaliptin + pioglitazone

60

5.4

8.5

12

27.9

57

37

78.7

 

76

metformin + pioglitazone

72

5.3

8.4

 

27.7

58

39

77.3

Forst, 2013 [45]

22

vildagliptin + metformin

100.8

5.0

7.41

6

Not available

Not available

Not available

99.3

 

22

glimepiride + metformin

73.2

5.6

7.28

 

Not available

Not available

Not available

93.7

Mikada, 2014 [47]

14

sitagliptin

91.2

6.5

7.45

6

28.8

59.2

11

76.8

 

14

miglitol

111.6

7.4

6.90

 

29.5

58.7

11

81.4

Hibuse, 2014 [48]

16

sitagliptin

57.6

6.7

7.5

3

24.9

63

9

Not available

 

10

sulfonylurea and/or biguanide

45.6

4.6

7.8

 

28.1

56

6

Not available

Takeshita, 2015 [49]

30

sitagliptin

86.4

4.5

6.7

4

24.5

61.0

18

62.5

 

30

mitiglinide

145.2

5.0

6.9

 

24.2

65.8

19

63.2

Derosa, 2012 [50]

84

vildagliptin + metformin

6.1

5.2

8.1

12

27.9

54.2

42

76.9

 

83

placebo + metformin

6.3

5.4

8.2

 

27.8

52.4

43

78.5

Derosa, 2014 [51]

86

vildagliptin

6.9

4.8

7.9

6

27.9

59.8

42

77.8

 

81

glimepiride

6.7

4.5

7.8

 

27.7

56.8

36

77.2

Takeshita, 2015 [52]

58

vildagliptin

Not available

3.6 

8.1

3

24.5

Not available

36

63.2

 

54

liraglutide

Not available

3.8

8.0

 

25.4

Not available

35

65.8

Shimoda, 2014 [53]

25

sitagliptin

Not available

7.0

7.3

3

24.9

63.9

16

Not available

 

25

glimepiride

Not available

7.6

7.5

 

25.3

62.4

15

Not available